Incidence and Survival of Testicular Cancers in a Province in Northern Italy and Their Association with Second Tumors.
histotype
incidence
mortality
second neoplasms
survival
testis cancer
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
10
10
2023
revised:
07
11
2023
accepted:
07
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
This study investigated the incidence, mortality, and 5-year survival rates of testicular cancers diagnosed in a northern Italian province, which were eventually associated with previous or subsequent extratesticular neoplasms. Cases from 1996 to 2020 were examined by age and histotype (seminoma vs. non-seminoma). The standardized incidence rate was calculated using the European population, and the annual percent change (APC) was reported. The five-year relative survival was estimated using the Pohar Perme method. The association with the second neoplasm was also evaluated. In our study, 385 patients with testicular cancer were included, most of whom were aged between 30 and 40 years. The non-seminoma and seminoma groups accounted for 44% and 18% of younger adults, respectively. The incidence rate increased during the study period (APC 1.6*); however, it increased in seminomas (APC 2.3*) but not in non-seminomas (APC -0.1). Conversely, the mortality rate remained constantly low either overall or in each of the two groups. The overall 5-year survival rate of testicular cancer patients was 95% (99% and 88% for seminomas and non-seminomas, respectively). Primary extratesticular tumors were documented in 37 cases, 18 after and 19 before the testicular cancer diagnosis. Our study confirms that the increased incidence and excellent survival rate are the prerogative of seminomas.
Identifiants
pubmed: 37998008
pii: biology12111409
doi: 10.3390/biology12111409
pmc: PMC10669588
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Genitourin Cancer. 2018 Aug;16(4):e785-e793
pubmed: 29605587
J Clin Oncol. 2014 Dec 1;32(34):3817-23
pubmed: 25267754
Urol Clin North Am. 2015 Aug;42(3):393-408
pubmed: 26216826
Clin Epidemiol. 2013 Oct 17;5:417-27
pubmed: 24204171
BMC Cancer. 2018 Feb 14;18(1):189
pubmed: 29444652
World J Urol. 2015 May;33(5):623-31
pubmed: 25030752
J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65
pubmed: 16174857
J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39
pubmed: 9326912
Cancer Epidemiol. 2012 Apr;36(2):217-21
pubmed: 21890445
Lancet Oncol. 2019 Apr;20(4):531-545
pubmed: 30797674
BMC Public Health. 2021 Sep 19;21(1):1707
pubmed: 34538241
Acta Oncol. 2014 Mar;53(3):342-50
pubmed: 23992111
PLoS One. 2019 Mar 28;14(3):e0214410
pubmed: 30921367
Ann Oncol. 2013 Feb;24(2):508-513
pubmed: 23110807
BMC Cancer. 2020 Apr 6;20(1):284
pubmed: 32252689
Int J Cancer. 2020 Jul 1;147(1):21-32
pubmed: 31597192
Eur J Cancer. 2015 Oct;51(15):2206-2216
pubmed: 26421823
Nat Rev Urol. 2012 Apr 17;9(6):339-49
pubmed: 22508459
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Medicina (Kaunas). 2022 Oct 24;58(11):
pubmed: 36363471
Medicina (Kaunas). 2023 Apr 07;59(4):
pubmed: 37109682
Urol Oncol. 2015 Sep;33(9):392-8
pubmed: 26072728
Ann Oncol. 2014 Nov;25(11):2173-2178
pubmed: 25210015
BMC Urol. 2019 Jul 10;19(1):64
pubmed: 31291913
Nat Rev Dis Primers. 2018 Oct 5;4(1):29
pubmed: 30291251